Kyverna Therapeutics
Develops miv-cel, an autologous CD19 CAR-T candidate for B-cell-driven autoimmune diseases.
$8.53
After-hours close+0.17 (+2.03%)
At close$8.36(−3.24%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.68 | — | — |
| Aug 2026 | −$0.68 | −$0.63 | +7.1% |
| Aug 2026 | −$0.68 | −$0.63 | +7.1% |
| May 2026 | −$0.75 | −$0.66 | +12.0% |
| Mar 2026 | −$0.85 | −$0.80 | +5.3% |
The latest year is open to everyone — the 12 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.68 | — | — | — | — | — |
| Aug 12, 2026 | −$0.68 | −$0.63 | +7.1% | — | — | — |
| Aug 11, 2026 | −$0.68 | −$0.63 | +7.1% | — | — | — |
| May 12, 2026 | −$0.75 | −$0.66 | +12.0% | — | — | — |
| Mar 26, 2026 | −$0.85 | −$0.80 | +5.3% | — | — | — |
The latest year is open to everyone — the 12 quarters behind it read with an account. Sign in | ||||||
| Nov 12, 2025 | ||||||
| Aug 12, 2025 | ||||||
| May 13, 2025 | ||||||
| Mar 27, 2025 | ||||||
| Nov 13, 2024 | ||||||
| Aug 12, 2024 | ||||||
| May 14, 2024 | ||||||
| Feb 8, 2024 | ||||||
| Sep 30, 2023 | ||||||
| Jun 30, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Dec 31, 2022 | ||||||